Yaxiong Zhang1, Shiyang Kang1, Wenfeng Fang2, Xuan Wu2, Wenhua Liang2. 1. Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China; 2. Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; ; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
Abstract
BACKGROUND: Previous meta-analyses of non-randomized studies suggested that the hepatitis B immunoglobulin (HBIG) and lamivudine (LAM) combination therapy was significantly better than HBIG or LAM alone in preventing hepatitis B virus (HBV) recurrence after transplantation. However, substantial evidences supporting the superiority of combination therapy are still insufficient. Therefore, we sought to conduct a multiple-treatment comparison to integrate current data which was based on randomized controlled trials (RCTs). METHODS: We searched electronic databases of PubMed, Embase and the Cochrane Library for eligible literatures. Pair-wise meta-analyses were to synthesize studies comparing the same pair of treatments. Appropriate networks for overall and 1-year recurrence rates were established. Bayesian algorithm was used in multiple-treatment comparisons to compare relative effects of all included regimens. RESULTS: Four RCTs on prophylaxis against HBV recurrence after liver transplantation, involving 162 participants, were included. HBIG mono-therapy, LAM mono-therapy and HBIG plus LAM showed no statistically difference in risk ratios (RRs) in terms of overall HBV recurrence rate in network meta-analysis. Nevertheless, HBIG mono-therapy had potential advantage compared with combination of HBIG and LAM in 1-year HBV recurrence rate [RR 0.00, 95% confidence interval (CI): 0.00 to 0.91] while the rest comparisons revealed no significance. The cumulative probabilities of treatments associated with the highest recurrence were (overall HBV recurrence rate, 1-year HBV recurrence rate): HBIG (18%, 1%), LAM (32%, 42%) and HBIG plus LAM (50%, 57%). CONCLUSIONS: This network meta-analysis based on data from RCTs showed no significant differences among HBIG mono-therapy, LAM mono-therapy, combination of HBIG and LAM in overall HBV recurrence rate after liver transplantation. Further well designed and large-scale RCTs are warranted to clarify these issues.
BACKGROUND: Previous meta-analyses of non-randomized studies suggested that the hepatitis B immunoglobulin (HBIG) and lamivudine (LAM) combination therapy was significantly better than HBIG or LAM alone in preventing hepatitis B virus (HBV) recurrence after transplantation. However, substantial evidences supporting the superiority of combination therapy are still insufficient. Therefore, we sought to conduct a multiple-treatment comparison to integrate current data which was based on randomized controlled trials (RCTs). METHODS: We searched electronic databases of PubMed, Embase and the Cochrane Library for eligible literatures. Pair-wise meta-analyses were to synthesize studies comparing the same pair of treatments. Appropriate networks for overall and 1-year recurrence rates were established. Bayesian algorithm was used in multiple-treatment comparisons to compare relative effects of all included regimens. RESULTS: Four RCTs on prophylaxis against HBV recurrence after liver transplantation, involving 162 participants, were included. HBIG mono-therapy, LAM mono-therapy and HBIG plus LAM showed no statistically difference in risk ratios (RRs) in terms of overall HBV recurrence rate in network meta-analysis. Nevertheless, HBIG mono-therapy had potential advantage compared with combination of HBIG and LAM in 1-year HBV recurrence rate [RR 0.00, 95% confidence interval (CI): 0.00 to 0.91] while the rest comparisons revealed no significance. The cumulative probabilities of treatments associated with the highest recurrence were (overall HBV recurrence rate, 1-year HBV recurrence rate): HBIG (18%, 1%), LAM (32%, 42%) and HBIG plus LAM (50%, 57%). CONCLUSIONS: This network meta-analysis based on data from RCTs showed no significant differences among HBIG mono-therapy, LAM mono-therapy, combination of HBIG and LAM in overall HBV recurrence rate after liver transplantation. Further well designed and large-scale RCTs are warranted to clarify these issues.
Authors: K W Lee; S K Lee; J W Joh; S J Kim; J H Park; S E Chon; S H Choi; J S Heo; S W Paik; K W Koh; J H Lee; M S Choi; Y I Kim; B B Lee Journal: Transplant Proc Date: 2001 Nov-Dec Impact factor: 1.066
Authors: N V Naoumov; A R Lopes; P Burra; L Caccamo; R M Iemmolo; R A de Man; M Bassendine; J G O'Grady; B C Portmann; G Anschuetz; C A Barrett; R Williams; M Atkins Journal: J Hepatol Date: 2001-06 Impact factor: 25.083
Authors: Rohit Loomba; Ayana K Rowley; Robert Wesley; Karen G Smith; T Jake Liang; Frank Pucino; Gyorgy Csako Journal: Clin Gastroenterol Hepatol Date: 2008-05-05 Impact factor: 11.382
Authors: María Buti; Antoni Mas; Martín Prieto; Fernando Casafont; Antonio González; Manuel Miras; Jose Ignacio Herrero; Rossendo Jardí; Eva Cruz de Castro; César García-Rey Journal: J Hepatol Date: 2003-06 Impact factor: 25.083
Authors: J D Eason; R B Freeman; R J Rohrer; W D Lewis; R Jenkins; J Dienstag; A B Cosimi Journal: Transplantation Date: 1994-06-15 Impact factor: 4.939